Chemotherapy

Pharmacology

Multiple-Dose Kinetic Study of Mefloquine in Healthy Male Volunteers

Mimica I.a · Fry W.a · Eckert G.b · Schwartz D.E.b

Author affiliations

aMedorbis Pesquisas Sociedade Civil Ltda., São Paulo, Brazil; bBiological Pharmaceutical Research Department, F. Hoffmann-La Roche & Co. Ltd., Basel, Switzerland

Related Articles for ""

Chemotherapy 1983;29:184–187

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Pharmacology

Published online: September 08, 2009
Issue release date: 1983

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: https://www.karger.com/CHE

Abstract

250 mg mefloquine was administered orally once a week for 21 consecutive weeks to 5 volunteers. Blood samples were collected just before administration of the next dose, and the unchanged drug and its metabolite, Ro 21-5104, were measured in the plasma. The mean plasma levels minima in individual subjects measured at steady state were for mefloquine between 0.56 and 1.25 μg/ml, and for the metabolite between 1.47 and 5.55 μg/ml. The corresponding metabolite to mefloquine ratios ranged between 2.3 and 8.6. The half-life of mefloquine determined at the end of the trial agreed fairly well with values measured in single dose kinetics. This suggests that induction or inhibition of the metabolizing enzymes did not occur during the period of administration.

© 1983 S. Karger AG, Basel




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Pharmacology

Published online: September 08, 2009
Issue release date: 1983

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: https://www.karger.com/CHE


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP